Experts Evaluated Single-Dose HPV Vaccination Potential

Researchers are reviewing new data to see if a single HPV shot could provide enough protection against cancer.

Updated on Sept. 26, 2026 in Cancer

Isometric editorial illustration of a single medical vaccine vial on a clinical surface, representing public health research. — The CDC is currently evaluating clinical data to determine if a single-dose HPV vaccination schedule can provide long-term protection against cancer. AI Illustration. Upload story photo >

Live Poll

Should federal health agencies adopt new vaccination schedules if recent studies suggest fewer doses work?

Medical experts are currently reviewing research, including a study showing high efficacy for a single-dose regimen, to determine if the U.S. vaccination schedule should be revised. This evaluation follows a legal battle over an earlier mandate to reduce the recommended HPV shots to one dose.

Why it matters

Simplifying the vaccination schedule could help improve uptake beyond the current 63% rate among teenagers, potentially reducing the 50,000 annual HPV-related cancer cases in the U.S. Officials are working to ensure any policy shift is backed by robust evidence.

A 2025 study in Costa Rica tracking 20,000 girls found that a single HPV shot provided approximately 97% protection against cervical cancer. Researchers are now investigating if these findings support a change to the national vaccination schedule.

The players

Robert F. Kennedy Jr.

The U.S. health secretary who issued an order to reduce the HPV vaccine dosing schedule to a single shot.

American Academy of Pediatrics

A professional organization of pediatricians that challenged the health secretary's order in court regarding vaccination guidance.

Centers for Disease Control and Prevention (CDC)

The federal agency overseeing public health recommendations, which is currently reviewing evidence for potential dosing changes.

The details

The HPV vaccine protects against strains of the virus that cause up to 90% of cervical and anal cancers. By potentially reducing the required doses to one, health officials aim to simplify the immunization process and increase coverage among adolescents. A CDC advisory committee has established a work group to rigorously analyze whether a single dose can sustain long-term immunological efficacy comparable to the established two-dose series.

2006: Federal officials approved the first HPV vaccine.
2016: The government reduced the recommended HPV vaccine doses from three to two.
2024: Research developments prompted a CDC advisory committee investigation.
January 2026: U.S. health secretary Robert F. Kennedy Jr. ordered a reduction to one dose.
September 2026: Recent research continues to fuel discussions on potential schedule revisions.

COVID-19
Sept. 18
Flu Vaccination Advice Issued Amid ACIP Impasse
COVID-19
Sept. 21
Governors Urged Caution on Federal Vaccine Policy Changes
Cancer
Sept. 22
U.S. Cancer Death Rates Have Continued to Fall

Health Landscape

This potential shift to a single-dose schedule follows the precedent set by the 2016 CDC HPV vaccine dosing schedule reduction, which saw the requirement shift from three doses to two. It reflects a broader effort to optimize immunization series to maximize public health impact.

If you have questions about the current HPV vaccination schedule for your child, discuss the latest official guidance with your pediatrician. It is important to stay updated, as health officials may revise recommendations as the ongoing review of single-dose effectiveness concludes.

The takeaway

Ongoing research suggests a single HPV dose may offer high levels of protection, though the multi-dose schedule remains the standard. Discuss the current vaccination requirements for your family with a healthcare provider to ensure adherence to the most recent evidence-based recommendations.